65.83 0.00 (0.00%)
After hours: 4:15PM EDT
|Bid||65.66 x 800|
|Ask||67.99 x 1000|
|Day's range||63.97 - 66.37|
|52-week range||26.56 - 78.75|
|Beta (5Y monthly)||1.42|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
(Bloomberg) -- Khloe Kardashian is adding another role to her already busy schedule, migraine ambassador.The social influencer, who has been criticized for past associations with weight loss teas and smoothies has joined forces with Biohaven Pharmaceutical Holding Co. to promote its migraine medicine, Nurtec ODT. Sales of the tablet in the first quarter were $1.2 million after the drug was approved in February.Nurtec ODT is seen generating about $50 million in revenue this year and topping $1 billion by 2024, according to the average of analysts’ estimates. Time will tell if its association with a Kardashian will spur the migraine medicine into what the industry calls blockbuster status sooner.More women suffer from migraines than men, and a smattering of new drugs has offered hope for the often disabling condition. Biohaven faces stiff competition from large-cap drugmakers like Amgen Inc. and the Danish drug company H. Lundbeck A/S. Shares in New Haven Connecticut-based Biohaven rose as much as 3.6% on Wednesday after the announcement.(Updates shares in fourth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
A hot new migraine drug, positive financials, and several promising drug candidates in late-stage trials are luring investors to this stock.
Anyone researching Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) might want to consider the historical...
Investors need to pay close attention to Biohaven Pharmaceutical (BHVN) stock based on the movements in the options market lately.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...